Elliptinium, a DNA intercalating agent with broad antitumor activity in a human tumor cloning system
- 1 November 1987
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 23 (11) , 1621-1626
- https://doi.org/10.1016/0277-5379(87)90440-8
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis.Journal of Clinical Oncology, 1985
- Phase II study of elliptinium in metastatic soft tissue sarcomaEuropean Journal of Cancer and Clinical Oncology, 1985
- Ellipticine derivatives interact with muscarinic receptorsBiochemical Pharmacology, 1985
- Phase I Study of Elliptinium (2-N-Methyl-9-Hydroxyellipticinium)Cancer Investigation, 1985
- Phase II study of 9-hydroxy-2N-methylellipticinium acetateEuropean Journal of Cancer and Clinical Oncology, 1984
- Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study)European Journal of Cancer and Clinical Oncology, 1982
- Drug Dependent Red Cell Antibodies and Intravascular Haemolysis Occurring in Patients Treated with 9 Hydroxy‐Methyl‐EllipticiniumBritish Journal of Haematology, 1980
- Preliminary trial of 9-hydroxy-2-methyl ellipticinium (NSC 264-137) in advanced human cancersPublished by Elsevier ,1978
- Primary Bioassay of Human Myeloma Stem CellsJournal of Clinical Investigation, 1977
- Primary Bioassay of Human Tumor Stem CellsScience, 1977